Anapharm Bioanalytics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Anapharm Bioanalytics is a privately held, revenue-generating bioanalytical CRO serving pharmaceutical, biotech, and generic drug companies worldwide. Founded in 2005, the company has built a strong reputation on high-quality standards, an outstanding regulatory track record with EU and FDA inspections, and deep expertise in LC-MS/MS and Ligand Binding Assay platforms. Its core business is providing full-service outsourcing for bioanalysis across all stages of drug development, with a particular emphasis on bioequivalence and clinical trials. Led by founder Dr. Maria Cruz Caturla, the company focuses on client-oriented service and timely data delivery to support drug approvals.

DiagnosticsProteomics

Technology Platform

Utilizes LC-MS/MS for small molecule analysis and Ligand Binding Assay (LBA) platforms (e.g., ELISA) for large molecule (biologics) bioanalysis. Maintains an extensive library of validated methods and offers custom method development.

Opportunities

The growing trend of pharmaceutical R&D outsourcing, the expansion of the generic drug market (driving bioequivalence studies), and the increasing complexity of biologics development all present significant demand for its specialized bioanalytical services.

Its strong regulatory track record is a key asset in this environment.

Risk Factors

Faces intense competition from other global and regional CROs.

Revenue is dependent on the cyclical R&D spending of pharmaceutical clients and is vulnerable to operational or regulatory missteps that could damage its reputation for quality, which is central to its value proposition.

Competitive Landscape

Operates in the competitive bioanalytical CRO segment, competing against large global full-service CROs (e.g., LabCorp, IQVIA, PPD), specialized central labs, and other niche bioanalytical providers. Differentiation is based on deep expertise in bioequivalence, a strong regulatory history, a client-focused model, and over 30 years of collective team experience.

More companies in Diagnostics & Precision Medicine →More companies in Spain →